|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary table 1. Overall survival, univariate and multivariate cox proportional hazards for patients treated with targeted agents** | | | | | | | |
| **Factor** | **Category** | **Median  overall survival (months)** | **Univariable** | | **Multivariable** | |
| **HR (95% CI)** | **p** | **HR (95% CI)** | **P** |
| **Age** | <60 yrs | 26.7 | 1 | 0.01 | 1 | <0.001 |
| ≥60 yrs | 9.8 | 2.06 (1.17-3.64) | 3.10 (1.61-5.97) |
| **Sex** | Female | 15.9 | 1 | 0.84 |  |  |
| Male | 14.7 | 1.06 (0.58-1.97) |  |  |
| **Nephrectomy** | No | 6.9 | 1 | 0.02 | 1 | 0.12 |
| Yes | 16.6 | 0.34 (0.14-0.82) | 0.47 (0.18-1.22) |
| **Metastatic disease** | Metachronous | 25.1 | 1 | 0.18 |  |  |
| Synchronous | 12.5 | 1.45 (0.84-2.52) |  |  |
| **Metastatic sites** | 1-2 | 21.2 | 1 | 0.04 | 1 | 0.001 |
| ≥3 | 8.1 | 1.99 (1.04-3.84) | 3.44 (1.63-7.23) |
| **Bone metastases** | No | 18.4 | 1 | 0.09 |  |  |
| Yes | 7.3 | 1.95 (0.91-4.19) |  |  |
| **Liver metastases** | No | 16.2 | 1 | 0.49 |  |  |
| Yes | 9.7 | 1.27 (0.64-2.56) |  |  |
| **Lung metastases** | No | 25.1 | 1 | 0.63 |  |  |
| Yes | 11.9 | 1.15 (0.66-1.99) |  |  |
| **Lymph node metastases** | No | 25.1 | 1 | 0.03 | 1 | 0.007 |
| Yes | 10.7 | 1.88 (1.06-3.31) | 2.35 (1.26-4.38) |
| **Brain metastases** | No | 16.5 | 1 | 0.35 |  |  |
| Yes | 8.9 | 1.35 (0.72-2.54) |  |
| **ECOG performance status** | 0 | 24.9 | 0.44 (0.24-0.81) | 0.008  <0.001 | 0.27 (0.14-0.52) | <0.001 |
| 1 | 10.0 | 1 |  | 1 |  |
| ≥2 | 5.3 | 1.19 (0.40-3.56) | 0.27 | 1.32 (0.41-4.31) | 0.64 |
| **MSKCC risk group** | Favourable | 26.0 | 0.81 (0.39-1.70) | 0.19 |  |  |
| Intermediate | 16.1 | 1 |  |  |  |
| Poor | 7.3 | 1.75 (0.88-3.50) | 0.06 |  |  |